Having pharmacologically validated the BRCA synthetic lethality, we performed a cell panel screen covering a diverse set of tumor indications to identify potential cancer subtypes with sensitivity to MSC778 beyond BRCA1/2-mediated HRD. This evidence concerns the gene BRCA1 and neoplasm.